NHMRC reports on progress to improve clinical trials
19 August, 2014The National Health and Medical Research Council (NHMRC), tasked with implementing a range of initiatives designed to make the process of initiating and conducting clinical trials in Australia significantly more efficient and cost effective, has reported on the progress of work under the initiative and advised it will update the information monthly.
Lead site for Innate's SPMS trial wins ethics nod
19 August, 2014 by Dylan Bushell-EmblingInnate Immunotherapeutics (ASX:IIL) announced that WANRI - lead site for its phase IIb trial of MIS416 in secondary progressive multiple sclerosis - has been cleared to start recruiting patients.
QRxPharma abandons MoxDuo development
15 August, 2014 by Dylan Bushell-EmblingQRxPharma (ASX:QRX) has ceased development of dual-opioid drug MoxDuo, after the board decided that the cost of additional trials sure to be required for US approval could not be justified.
Industry leaders propose AIM Incentive to boost innovation
14 August, 2014Australian industry leaders have proposed an Australian Innovation & Manufacturing (AIM) Incentive in submissions to the Senate's inquiry into Australia's innovation system.
Perth's Orthocell lists on ASX
13 August, 2014 by Dylan Bushell-EmblingOrthocell (ASX:OCC) has listed on the ASX following last month's $8m IPO and started receiving royalty revenue from China for regenerative medicine product Ortho-ACI.
CSL's FY14 profit grows 8% to $1.4bn
13 August, 2014 by Dylan Bushell-EmblingCSL (ASX:CSL) has reported an 8% growth in FY14 profit, despite the impact of a legal settlement and a decline in sales at its bioCSL division.
Bespoke biotech
13 August, 2014 by Tim DeanAdditive manufacturing and 3D printing technology have a lot to offer makers of biomedical devices.
International bio-industry associations join to comment on the USPTO's subject matter eligibility guidance
12 August, 2014 by Anna LavelleBiotech industry associations join forces to express concerns about changes to US non-statutory patent law.
Phosphagenics completes IND-enabling pain patch study
11 August, 2014 by Dylan Bushell-EmblingPhosphagenics (ASX:POH) achieved encouraging results from the first of two planned IND-enabling phase I trials of pain patch TPM/oxymorphone.
GI Dynamics recruiting for EndoBarrier utility trial
11 August, 2014 by Dylan Bushell-EmblingGI Dynamics (ASX:GID) has signed on the first obese patients for a utility trial of EndoBarrier in France and reported year-on-year revenue growth but a wider net loss for Q1.
Mesoblast MPCs to be trialled in end-stage heart failure
08 August, 2014 by Dylan Bushell-EmblingMesoblast and the US National Institutes of Health will team up for a 120-patient trial of the company's MPCs in end-stage heart failure.
Clinuvel rejects $95m takeover offer
08 August, 2014 by Dylan Bushell-EmblingClinuvel (ASX:CUV) has declined a takeover bid from US-based Retrophin, with the board electing to focus the company's efforts on pursuing EMA approval for Scenesse in skin condition EPP.
AusBiotech submits to Senate Inquiry into Australia's Innovation System
07 August, 2014AusBiotech's substantive submission to the Senate Standing Committee on Economics' Australian Innovation System inquiry has called for tax reform, support for commercialisation, incentives for commercial thinking and clinical trial reform.
Immuron's Travelan launches in Canada
06 August, 2014 by Dylan Bushell-EmblingImmuron's (ASX:IMC) distribution partner Paladin Labs has launched OTC travellers' diarrhoea treatment Travelan in Canada.
AOD9604 awarded safe status in US
06 August, 2014 by Dylan Bushell-EmblingCalzada (ASX:CZD) said its peptide AOD9604 has secured Generally Recognised As Safe status in the US, allowing its use in food and supplements at a daily level of up to 1 mg per person.
